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1. Introduction 
We have reported earlier that the administration of
the dibutyryl derivative of cyclic AMP or theophylline 
to normal rats results in a sharp increase in the liver 
ornithine decarboxylase activity [1,2]. This effect, also 
noticed by Beck et al. [3], was abolished by inhibitors 
of RNA and protein synthesis, but not by adrenalec- 
tomy [1,2]. As discussed earlier [2], several mechanisms 
may operate in the stimulation Of liver ornithine decar- 
boxylase activity by the nucleotide in intact rats. The 
present results indicate that an intact hypophysis 
needed for the stimulation. Furthermore, it was 
observed that chlorpromazine and vasopressin are 
potent stimulators of this enzyme in the rat liver. 
2: Materials and methods 
Where not otherwise indicated, the animals used 
were female Wistar rats weighing 110-140 g. Hypo- 
physectomized female Sprague-Dawley rats were 
supplied by the Charles River Breeding Laboratories, 
Inc., Wilmington, Mass. Hypophysectomy was performed 
11 to 13 days before use. All animals were deprive~ 
of food for 12 to 14 hr before sacrifice and were 
killed between 8 and 10 a.m. to avoid diurnal variations 
in ornithine decarboxylase activity. 
N 6, 02'-Dibutyryl cyclic AMP (dibutyryl cAMP), 
synthetic arginine vasopressin and synthetic lysine 
vasopressin were purchased from Sigma. Chlorproma- 
zine chloride was supplied by Oy Medikalis Ab, 
Helsinki. Propranolol chloride (lnderal ~) was obtained 
through Imperial Chemical tnctustries (ICI). L-Dopa 
(L-3,4-dihydroxyphenylalanine) was a product of E. 
Merck, Darmstadt. DL-Ornithine- 1-x 4 C (spec.act. 2.74 
mCi/mmol) was purchased from the New England 
Nuclear Corporation. Before use it was treated with 
acid as described earlier [2]. 
Ornithine decarboxylase activity was assayed from 
the 100 000 g supernatant fraction of a liver homo- 
genate as described earlier [2], using 1 mM L-ornithine- 
1-14C as the substrate. None of the above-mentioned 
drugs had any effect on the enzyme activity, when 
added directly to the assay mixture. The experimental 
groups were compared by means of the t-test. 
3. Results and discussion 
Our previous results indicated that the stimulation 
of liver ornithine decarboxylase activity by dibutyryl 
cAMP in intact rats represented synthesis de novo of 
the enzyme, and that the stimulation was probably 
not mediated by adrenal cortical hormones [2]. It 
has been reported that the administration of dibutyryl 
cAMP can release several hormones, uch as insulin, 
glucagon and growth hormone [4], which all are 
able to increase liver ornithine decarboxylase activity, 
see [5,6]. To evaluate the role of growth hormone, a
very potent inducer of liver ornithine decarboxylase 
[6], in mediating the nucleotide ffect, several other 
drugs able to release growth hormone in anesthetized 
rats [7] were tested. As shown in table 1, arginine and 
lysine vasopressins markedly raised the ornithine decar- 
boxylase activity both in normal and in adrenalec- 
tomized rats. This effect could not be abolished by a 
simultaneous administration of propranolol (400/~g/ 
100 g), a ~-adrenergic blocking agent, which has been 
reported to inhibit growth hormone release by 
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Table 1 
Stimulation of liver ornithine decarboxylase by vasopressins 
in normal and adrenalectomized rats 
Table 2 
Effect of chlorpromazine on liver ornithine decarboxylase 
activity in intact rats 
Treatment 
Ornithine decarboxylase 
(pmoles/mg protein per 30 min) 
Unoperated Adrenalectomized 
Time of Ornithine decarboxylase 
treatment (hr) pmoles ~* CO 2/mg prot 
per 30 min 
Saline 70-+ 19 49-+ 10 
Arg-vasopressin 384 -+ 1152 260 +- 252 
Lys-vasopressin 1125 -+ 3112 1194 -+ 1752 
~p < 0.05; 2p < 0.01 The significance of the differences as 
compared with the saline-treated controls. 
Vasopressins (400 mU/100 g body weight) were injected 
intraperitoneally in 0.5 ml of 0.9% NaC1 at 3.5 hr before 
killing. Adrenalectomy had been performed 10 days 
earlier. The values are means ± S.D. of four to five animals. 
3 (saline) 18 -+ 8 
2 87 -+ 362 
3 121 -+ 682 
4 160 -+ 742 
5 223 -+ 155 ~ 
6 149 -+ 103 ~ 
~p < 0.05; 2p < 0.01 The significance of the differences as 
compared with the saline-treated controls. 
Chlorpromazine (2 mg/100 gbody weight) in 0.5 ml of 
0.9% NaC1 was injected intraperitoneally. The values are 
means -+ S.D. of five animals. 
arginine vasooressin anesthetized rats [71. 
Propranolol alone had no effect on liver ornithine 
decarboxylase activity (data not shown). Table 2 shows 
that also chlorpromazine treatment increased ornithine 
decarboxylase activity in the liver. L-Dopa (1 mg/100 g), 
which is reported to inhibit the chlorpromazine- 
stimulated release of growth hormone [7], neither 
changed the basal level of liver ornithine decarboxylase 
activity nor prevented the stimulation of the enzyme 
activity by chlorpromazine (data not shown). 
The results obtained with vasopressins and chlor- 
promazine are in line with the possibility that the 
stimulation of liver ornithine decarboxylase by 
dibutyryl cAMP in intact rats may be mediated 
through the growth hormone release. We therefore 
studied the effect of the cyclic nucleotide derivative 
on ornithine decarboxylase activity in rats hypo- 
physectornized 11 to 13 days earlier. As shown in 
table 3, dibutyryl cAMP had no effect on the liver 
ornitb_ine decarboxylase activity in hypophysectomized 
rats, although it significantly increased this enzyme 
activity in unoperated animals 4 hr after the admini- 
stration. Also the difference in ornithine decarboxylase 
Table 3 
Effect of dibutyryl cyclic AMP (DBcAMP) on liver ornithine 






pmoles ~4 CO~/mg prot 
per 30 min 
Unoperated Hypophysectomized 
Saline 4 50-+ 16 22_+ 10 
DBcAMP 4 506 ~ 369 ~ 26 _+ 2 
DBcAMP 6 58-+ 21 30-+ 2 
t p < 0.05 The significance of the differences as compared with the saline- 
treated controls. 
DBcAMP (5/mg per animal) was given intraperitoneally in 0.5 ml of 0.9% 
NaCI. At the same time of analysis the body weight was 80-115 g for 
hypophysectomized animals and 120-160 g for unoperated controls. 
The values are means of 3 to 5 animals in each group. 
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activities between the unoperated controls and the 
hypophysectomized group was statistically significant 
at 4 hr after the treatment (p < 0.05). We therefore 
conclude that intact hypophyses are needed for the 
stimulation. Our results are at variance with those 
reported by Richman et al. [8], who observed increases 
in the ornithine decarboxylase activities in the livers, 
kidneys, and adrenals of hypophysectomized rats 
after treatment with the nucleotide derivative. It 
appears, however, that in the latter study dibutyryl 
cAMP was given immediately after hypophysectomy, 
which might explain differing results. This inference 
is also in line with the report of Levine et al. [9], 
demonstrating a progressive fall in the responsiveness 
of adrenal ornithine decarboxylase to ACTH with 
increasing time after hypophysectomy. 
A number of different stimuli, including several 
peptide and steroid hormones, are able to enhance 
ornithine decarboxylase activity in specific target 
tissues. We have earlier speculated on the possibility 
that all these agents capable of inducing ornithine 
decarboxylase might have a common mediator, e.g. 
cyclic AMP, because treatment with several hormones 
can increase the level of intracellular cyclic cAMP, and 
because xogenously administered dibutyryl cAMP 
is able to stimulate ornithine decarboxylase activity 
[1,6]. A similar suggestion has also been presented 
by Beck et al. [3]. Some recent observations, e.g. a 
stimulation of ornithine decarboxylase activity by 
exogenous cyclic AMP or its dibutyryl derivative in 
the oviduct of Coturnix quail [ 10], in the cultured 
mammary tissue of mice [1 1], and in BHK cells in 
cultures [12], could be taken as additional support 
of the above hypothesis. A role for a cyclic AMP- 
dependent protein kinase in the regulation of 
orinthine decarboxylase activity has also been 
suggested by Byus and Russell [13]. However, 
estradiol given in vivo has been shown to increase 
ornithine decarboxylase activity in the rat uterus with- 
out changing the concentration of cyclic AMP [ 14]. 
Furthermore, the addition of serum or insulin to 
cell cultures is able to stimulate ornithine decarboxylase, 
but it decreases the level of cyclic AMP [ 12]. Large 
doses of growth hormone have been shown to 
enhance the adrenal ornithine decarboxylase activity 
without elevating cyclic AMP levels [8]. These latter 
observations, taken together with the present results 
obtained with hypophysectomized rats, render it 
unlikely that cyclic AMP would act as a common 
mediator in the hormonal control of orithine decar- 
boxylase activity. A possible role of cyclic GMP in 
this process remains to be elucidated. 
In the light of the present results it appears that 
exogenous cyclic AMP given to intact rats may induce 
ornithine decarboxylase by releasing some pituitary 
factor(s), e.g. growth hormone. On the other hand, 
some hypophyseal factor(s) may, directly or indirectly, 
control the synthesis of some undetermined cellular 
component(s) (e.g. protein kinase) possibily involved 
in the stimulation of ornithine decarboxylase activity. 
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